Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate

International Journal of Antimicrobial Agents

Volumn 20, Issue 4, 2002, Pages 235-247

  File Jr, Thomas M ^a   Jacobs, Michael R ^b   Poole, Michael D ^c   Wynne, Brian ^d  

^a SUMMA HEALTH SYSTEM   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Penicillin resistance; Pharmacokinetically enhanced amoxycillin clavulanate; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CLARITHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ADULT; ARTICLE; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INFECTION RISK; MALE; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 0036776002     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00130-9     Document Type: Article

References (35)

1. Kaliner M.A., Osguthorpe J.D., Fireman P., et al. Sinusitis: bench to bedside. Current findings, future directions. Otolaryngol. Head Neck Surg. 116:1997;S1-20.
2. Spangler S.K., Jacobs M.R., Pankuch G.A., Appelbaum P.C. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9429 and RP 67829. J. Antimicrob. Chemother. 31:1993;273-280.
3. Guest J.F., Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur. Respir. J. 10:1997;1530-1534.
4. Meyer R.D., Finch R.G. Community-acquired pneumonia. J. Hosp. Infect. 22:(Suppl. A):1992;51-59.
5. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. New Engl. J. Med. 333:1995;1618-1624.
6. Gwaltney J.M. Jr, Scheld W.M., Sande M.A., Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a 15-year experience at the University of Virginia and review of other selected studies. J. Allergy Clin. Immunol. 90:1992;457-462.
7. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 117:(Suppl. 2):2000;S380-385.
8. Fass R.J. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J. Antimicrob. Chemother. 32:(Suppl. A):1993;17-27.
9. Appelbaum P.C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:1992;77-83.
10. Doern G.V., Heilmann K.P., Huynh H.K., Rhomberg P.R., Coffman S.L., Brueggemann A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:2001;1721-1729.
11. Felmingham D., Grüneberg R.N. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45:2000;191-203.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved Standard, 5th ed. M7-A5, Wayne, PA: NCCLS, 2000.
13. Craig W.A. Introduction. Respir. Med. 95:(Suppl. A):2001;S2-4.
14. Data on file, GlaxoSmithKline.
15. Felmingham D, Jacobs MR, Appelbaum PC. The Alexander Project 1998 - susceptibility of community-acquired LRTI isolates of Streptococcus pneumoniae to macrolide and lincosamide antibiotics (abstract P107), 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, 28-31 May, 2000.
16. Perez-Trallero E., Fernandez-Mazarrasa C., Garcia-Rey C., et al. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob. Agents Chemother. 45:2000;3334-3340.
17. Ball P., Geddes A., Rolinson G. Amoxycillin clavulanate: an assessment after 15 years of clinical application. J. Chemother. 9:1997;167-198.
18. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000;123(1 Pt 2):5-31.
19. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the drug-resistant Streptococcus pneumoniae Therapy Working Group. Arch. Intern. Med. 160:2000;1399-1408.
20. Dagan R., Klugman K.P., Craig W.A., et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 47:2001;129-140.
21. Garau J. Clinical failures: the tip of the iceberg? Respir Med 2001;95(Suppl. A):S5-11
22. Craig W.A. Re-evaluating current antibiotic therapy. Respir. Med. 95:(Suppl. A):2001;S12-S19.
23. Kaye C.M., Allen A., Perry S., et al. The clinical pharmacokinetics of a new pharmacokinetically-enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:2001;578-584.
24. Committee for Proprietary Medicinal Products. Note for guidance on evaluation of new antibacterial medicinal products. European Agency for the Evaluation of Medicinal Products, CPMP/EWP/558/95; 1997.
25. Marchant C.D., Carlin S.A., Johnson C.E., Shurin P.A. Measuring the comparative efficacy of antibacterial agents for acute otitis media: the 'Pollyanna phenomenon'. J. Pediatr. 120:1992;72-77.
26. Adelglass J., de Abate C.A., McElvaine P., Fowler C.L., LoCocco J., Campbell T. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol. Head Neck Surg. 120:1999;320-327.
27. Lasko B., Lau C.Y., Saint-Pierre C., Reddington J.L., Martel A., Anstey R.J. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. J. Int. Med. Res. 26:1998;281-291.
28. Fogarty C.M., Greenberg R.N., Dunbar L., et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin. Ther. 23:2001;425-439.
29. Shah P.M., Maesen F.P., Dolmann A., Vetter N., Fiss E., Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J. Antimicrob. Chemother. 43:1999;529-539.
30. Vetter N., Argryopoulou-Pataka P., Droszcz W., et al. Efficacy and safety of once-daily and twice-daily clarithromycin formulations in the treatment of acute exacerbations of chronic bronchitis. Adv. Ther. 16:1999;13-21.
31. Balgos A., Rodriguez-Gomez G., Nasnas R., et al. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections. Int. J. Clin. Pract. 53:1999;325-330.
32. Ball P., Geddes A., Rolinson G. Amoxycillin clavulanate: an assessment after 15 years of clinical application. J. Chemother. 9:1997;167-198.
33. Fremaux A., Sissa G., Geslin P. Trends of antibiotic resistance of pneumococci in France in 1987-1997: impact upon antibiotic therapy of pneumococcal infections. Antibiotiques. 1:1999;93-97.
34. Berry V, Singley C, Satterfield J, Woodnutt G. Efficacy of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae (Sp) (abstract 988), 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 22-25 September, 2001.
35. Ball P, Baquero F, Cars O, et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. The Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. J Antimicrob Chemother 2002;49:31-40.